Literature DB >> 23689482

Nephronectin expression in glomeruli of renal biopsy specimens from various kidney diseases: nephronectin is expressed in the mesangial matrix expansion of diabetic nephropathy.

Shinya Nakatani1, Eiji Ishimura, Katsuhito Mori, Shinya Fukumoto, Shotaro Yamano, Min Wei, Masanori Emoto, Hideki Wanibuchi, Masaaki Inaba.   

Abstract

BACKGROUND: In a previous proteomic study, we detected increased expression of nephronectin in the glomeruli from patients with diabetic nephropathy (DN). The aim of the present study was to clarify the usefulness of determining glomerular expression of nephronectin in kidney disease.
METHODS: We performed immunohistochemical staining for nephronectin in renal biopsy specimens from patients with a variety of kidney diseases (n = 190). The percentage of nephronectin-positive areas in the glomeruli was analyzed using an image analyzer.
RESULTS: Nephronectin immunoreactivity was clearly, strongly positive in the mesangial expansion and nodular lesions of DN (n = 18), whereas nephronectin immunoreactivity was negative in IgA glomerulonephritis, membranoproliferative glomerulonephritis, lupus nephritis, membranous glomerulonephritis, minor glomerular abnormalities, crescentic glomerulonephritis, and other kidney diseases, such as amyloidosis and light chain deposition disease. Nephronectin was stained weakly in sclerotic lesions, such as focal segmental glomerulosclerosis and hypertensive nephropathy. The percentage of nephronectin-positive areas in the glomeruli from DN patients [15.1 ± 4.7% (n = 18)] was significantly higher than that for other kidney diseases [5.5 ± 3.6% (n = 172)] (p < 0.001). In multiple regression analyses, fasting plasma glucose and hemoglobin A1c were significantly associated with the increase in the percentage of nephronectin-positive areas in the glomeruli (β = 0.23, p < 0.001 and β = 0.16, p = 0.045, respectively).
CONCLUSIONS: The expression of nephronectin was sufficient to discriminate DN from other kidney diseases with mesangial matrix expansion and nodular lesions. We consider that nephronectin staining could be helpful in the diagnosis of DN.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23689482     DOI: 10.1159/000350816

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  6 in total

1.  Podocytes regulate the glomerular basement membrane protein nephronectin by means of miR-378a-3p in glomerular diseases.

Authors:  Janina Müller-Deile; Jan Dannenberg; Patricia Schroder; Meei-Hua Lin; Jeffrey H Miner; Rongjun Chen; Jan-Hinrich Bräsen; Thomas Thum; Jenny Nyström; Lynne Beverly Staggs; Hermann Haller; Jan Fiedler; Johan M Lorenzen; Mario Schiffer
Journal:  Kidney Int       Date:  2017-05-03       Impact factor: 10.612

2.  Nephronectin Regulates Mesangial Cell Adhesion and Behavior in Glomeruli.

Authors:  Susan E Zimmerman; Chitkale Hiremath; Jun Tsunezumi; Zhufeng Yang; Bronwyn Finney; Denise K Marciano
Journal:  J Am Soc Nephrol       Date:  2018-01-15       Impact factor: 10.121

3.  Nephronectin (NPNT) and the prediction of nephrotic syndrome response to steroid treatment.

Authors:  Mona Mohamed Watany; Hemat El-Sayed El-Horany
Journal:  Eur J Hum Genet       Date:  2018-06-11       Impact factor: 4.246

4.  Antibodies against nephronectin ameliorate anti-type II collagen-induced arthritis in mice.

Authors:  Shigeyuki Kon; Machiko Honda; Kiyoshi Ishikawa; Masahiro Maeda; Tatsuya Segawa
Journal:  FEBS Open Bio       Date:  2019-11-24       Impact factor: 2.693

5.  Elevated glucose alters global gene expression and tenascin-C alternative splicing in mesangial cells.

Authors:  Maria E Vega; John B Finlay; Mansi Vasishtha; Jean E Schwarzbauer
Journal:  Matrix Biol Plus       Date:  2020-09-30

6.  A Tight Control of Non-Canonical TGF-β Pathways and MicroRNAs Downregulates Nephronectin in Podocytes.

Authors:  Nina Sopel; Alexandra Ohs; Mario Schiffer; Janina Müller-Deile
Journal:  Cells       Date:  2022-01-03       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.